Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Arnau de Vilanova (47)

2024

  1. Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?

    Pharmaceuticals, Vol. 17, Núm. 4

  2. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

2023

  1. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies

    Journal of Neurology, Vol. 270, Núm. 5, pp. 2380-2391

  2. Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 9, Núm. 2

  3. Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence, Vol. 17, pp. 1431-1439

  4. Monitoring response to disease-modifying treatment in multiple sclerosis

    Neurology Perspectives, Vol. 3, Núm. 2

  5. Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset

    Multiple Sclerosis Journal, Vol. 29, Núm. 14, pp. 1776-1785

  6. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  7. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  8. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 68

  2. Gadolinium-enhanced brain lesions in multiple sclerosis relapse

    Neurologia, Vol. 37, Núm. 7, pp. 557-563

  3. Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 64

  4. Measuring productivity loss in early relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 58

  5. Preventive treatment can reverse cognitive impairment in chronic migraine

    Journal of Headache and Pain, Vol. 23, Núm. 1

  6. Seroprevalence of SARS‐CoV‐2 in a Cohort of Patients with Multiple Sclerosis under Disease‐Modifying Therapies

    Journal of Clinical Medicine, Vol. 11, Núm. 9

2021

  1. Assessing blood-based biomarkers to define a therapeutic window for natalizumab

    Journal of Personalized Medicine, Vol. 11, Núm. 12

  2. Direct costs of relapses in patients with relapsing-remitting multiple sclerosis

    Neurology Perspectives, Vol. 1, Núm. 3, pp. 160-169

  3. High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions

    Patient, Vol. 14, Núm. 2, pp. 241-248

  4. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies

    Neurodegenerative Disease Management, Vol. 11, Núm. 3, pp. 251-261